Author

J. Poirier

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1

Frequent Co-Authors

C. M. Rudin· 2 shared K.-k. Wong· 2 shared T. Papagiannakopoulos· 2 shared Y. Hao· 2 shared A. G. Reidenbach· 1 shared A. Hata· 1 shared A. Herrera· 1 shared A. Lopez· 1 shared

Activity by Year

2022-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. M. Rudin

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

R. Pillai, S. E. LeBoeuf, Y. Hao, C. New, J. Blum, A. Rashidfarrokhi, S. M. Huang, C. Bahamon, W. L. Wu, B. Karadal-Ferrena, A. Herrera, E. Ivanova, M. Cross, J. P. Bossowski, H. Ding, , T. Papagiannakopoulos

This study shows that DRP-104, a glutamine antagonist, suppresses KEAP1 mutant lung tumor growth and enhances response to checkpoint blockade by inhibiting glutamine metabolism and improving T cell function.

bioRxiv · Jun 27, 2023 · PreprintCancer Biology

Targeted spectroscopy in the eye fundus

N. Lapointe, C. Akitegetse, J. Poirier, M. Picard, P. Sauvageau, D. Sauvageau

This paper demonstrates targeted ocular spectroscopy for imaging and spectral analysis of the eye fundus, showing its ability to detect biomarkers and assess blood oxygen saturation in vivo.

bioRxiv · Apr 27, 2023Biophysics

In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1-mutant lung cancer

J. Deng, D. H. Peng, D. Fenyo, Y. Hao, A. Lopez, D. Levin, M. Meynardie, M. Quinteros, M. Ranieri, S. Sahu, S. Lau, E. Shum, V. Velcheti, S. R. Punekar, N. Rekhtman, , K.-K. Wong

The paper identifies CD38 as a therapeutic target in LKB1-mutant lung cancer through in vivo metabolomics and shows that targeting CD38 inhibits tumor growth.

bioRxiv · Apr 18, 2023 · PreprintCancer Biology

Diversity-oriented synthesis encoded by deoxyoligonucleotides

L. Hudson, J. W. Mason, M. V. Westphal, M. J. R. Richter, J. R. Thielman, B. K. Hua, C. J. Gerry, G. Xia, H. L. Osswald, J. M. Knapp, Z. Y. Tan, P. Kokkonda, B. I. C. Tresco, S. Liu, A. G. Reidenbach, , K. Briner

The paper describes the design, synthesis, and validation of a 3.7 million-member DNA-encoded library using diversity-oriented synthesis to enhance structural diversity for drug discovery.

bioRxiv · Oct 16, 2022Biochemistry